First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW Meeting Abstract
| Authors: | Kang, Y. K.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Lordick, F.; Van Cutsem, E.; Ilson, D. H.; Klempner, S. J.; Yamaguchi, K.; Nakajima, T.; Cao, Y. J.; Li, R.; Moran, D.; Pophale, R. R.; Ranganath, R.; Xu, R. H. |
| Abstract Title: | First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S895 |
| Language: | English |
| ACCESSION: | WOS:001326612902060 |
| DOI: | 10.1016/j.annonc.2024.08.1504 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1438P -- Source: Wos |
